A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia-A nationwide study

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Risperidone long-acting injection (RLAI), the first licensed, long-acting second-generation antipsychotic (SGA), has not yet been studied in terms of its effectiveness compared with first-generation antipsychotic (FGA) LAIs. Methods: The differences in the effectiveness of RLAI and two other FGA LAIs, haloperidol and flupentixol, were assessed by conducting a one-year pre-post study based on the Taiwanese National Health Insurance Research Database. Effectiveness was defined as reduced medical care utilization and relapse prevention. Results: A decreased number of relapses were identified in the haloperidol injection group in the post-LAI period than in the pre-LAI period (Wilcoxon signed rank test, p. <. 0.05). The RLAI group had the largest number of acute admissions and relapses, the longest duration of admission (Wilcoxon signed rank test, p. <. 0.005), and the lowest utilization of anticholinergic agents, such as benzodiazepine (BZD) and SGAs (except oral risperidone), among all of the LAI groups in the post-LAI period. Conclusions: According to the results of this observational study, we suggest that the effectiveness of RLAI is not superior to that of FGA (haloperidol or flupentixol) LAIs, but that RLAI might have fewer adverse effects.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalSchizophrenia Research
Volume169
Issue number1-3
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Flupenthixol
Risperidone
Haloperidol
Schizophrenia
Antipsychotic Agents
Injections
Nonparametric Statistics
Recurrence
National Health Programs
Cholinergic Antagonists
Secondary Prevention
Benzodiazepines
Observational Studies
Databases
Research

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{0cc8c180dab64a1da17663aa39600d44,
title = "A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia-A nationwide study",
abstract = "Background: Risperidone long-acting injection (RLAI), the first licensed, long-acting second-generation antipsychotic (SGA), has not yet been studied in terms of its effectiveness compared with first-generation antipsychotic (FGA) LAIs. Methods: The differences in the effectiveness of RLAI and two other FGA LAIs, haloperidol and flupentixol, were assessed by conducting a one-year pre-post study based on the Taiwanese National Health Insurance Research Database. Effectiveness was defined as reduced medical care utilization and relapse prevention. Results: A decreased number of relapses were identified in the haloperidol injection group in the post-LAI period than in the pre-LAI period (Wilcoxon signed rank test, p. <. 0.05). The RLAI group had the largest number of acute admissions and relapses, the longest duration of admission (Wilcoxon signed rank test, p. <. 0.005), and the lowest utilization of anticholinergic agents, such as benzodiazepine (BZD) and SGAs (except oral risperidone), among all of the LAI groups in the post-LAI period. Conclusions: According to the results of this observational study, we suggest that the effectiveness of RLAI is not superior to that of FGA (haloperidol or flupentixol) LAIs, but that RLAI might have fewer adverse effects.",
author = "Yu, {Hsaing Yuan} and Hsiao, {Chih Yin} and Kao-Ching Chen and Lan-Ting Lee and Wei-Hung Chang and Mei-Hung Chi and I-Hui Lee and Po-See Chen and Yen-Kuang Yang",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.schres.2015.09.006",
language = "English",
volume = "169",
pages = "400--405",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia-A nationwide study

AU - Yu, Hsaing Yuan

AU - Hsiao, Chih Yin

AU - Chen, Kao-Ching

AU - Lee, Lan-Ting

AU - Chang, Wei-Hung

AU - Chi, Mei-Hung

AU - Lee, I-Hui

AU - Chen, Po-See

AU - Yang, Yen-Kuang

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Risperidone long-acting injection (RLAI), the first licensed, long-acting second-generation antipsychotic (SGA), has not yet been studied in terms of its effectiveness compared with first-generation antipsychotic (FGA) LAIs. Methods: The differences in the effectiveness of RLAI and two other FGA LAIs, haloperidol and flupentixol, were assessed by conducting a one-year pre-post study based on the Taiwanese National Health Insurance Research Database. Effectiveness was defined as reduced medical care utilization and relapse prevention. Results: A decreased number of relapses were identified in the haloperidol injection group in the post-LAI period than in the pre-LAI period (Wilcoxon signed rank test, p. <. 0.05). The RLAI group had the largest number of acute admissions and relapses, the longest duration of admission (Wilcoxon signed rank test, p. <. 0.005), and the lowest utilization of anticholinergic agents, such as benzodiazepine (BZD) and SGAs (except oral risperidone), among all of the LAI groups in the post-LAI period. Conclusions: According to the results of this observational study, we suggest that the effectiveness of RLAI is not superior to that of FGA (haloperidol or flupentixol) LAIs, but that RLAI might have fewer adverse effects.

AB - Background: Risperidone long-acting injection (RLAI), the first licensed, long-acting second-generation antipsychotic (SGA), has not yet been studied in terms of its effectiveness compared with first-generation antipsychotic (FGA) LAIs. Methods: The differences in the effectiveness of RLAI and two other FGA LAIs, haloperidol and flupentixol, were assessed by conducting a one-year pre-post study based on the Taiwanese National Health Insurance Research Database. Effectiveness was defined as reduced medical care utilization and relapse prevention. Results: A decreased number of relapses were identified in the haloperidol injection group in the post-LAI period than in the pre-LAI period (Wilcoxon signed rank test, p. <. 0.05). The RLAI group had the largest number of acute admissions and relapses, the longest duration of admission (Wilcoxon signed rank test, p. <. 0.005), and the lowest utilization of anticholinergic agents, such as benzodiazepine (BZD) and SGAs (except oral risperidone), among all of the LAI groups in the post-LAI period. Conclusions: According to the results of this observational study, we suggest that the effectiveness of RLAI is not superior to that of FGA (haloperidol or flupentixol) LAIs, but that RLAI might have fewer adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84942154788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942154788&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2015.09.006

DO - 10.1016/j.schres.2015.09.006

M3 - Article

VL - 169

SP - 400

EP - 405

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -